PATENT CLAIM ANALYSIS

Application Number: 16340352
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-08
Patent Classification: ["514", "450000"]

Abstract:
A method of treating a glycosylation-defective protein associated disease or disorder in a subject, the method includes administering to the subject a therapeutically effective amount of a Sarco/ER ATPase (SERCA) inhibitor.

Claim (Index 18):
The method of  claim 11 , the sensory deficit associated with the  N48K  destabilizing missense mutation in the human clarin-1 protein (hCLRN1 N48K ).

Metadata:
- Claim Count in Document: 7.0
- Percentile: 100.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15526663', '12056192', '13160291', '15939218', '15662546']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7468264055555885
- 35 USC 102 Novelty (BERT): 0.4736439908952118
- Combined Prediction Score: 0.7195081640895509
- Mean Citation Score: 142.32947
- Max Citation Score: 152.72707
- Similarity Product: 112.00098256296634

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test